TY  - GEN
AU  - Brunnberg,U
AU  - Mohr,M
AU  - Noppeney,R
AU  - Dürk,H A
AU  - Sauerland,M C
AU  - Müller-Tidow,C
AU  - Krug,U
AU  - Koschmieder,S
AU  - Kessler,T
AU  - Mesters,R M
AU  - Schulz,C
AU  - Kosch,M
AU  - Büchner,T
AU  - Ehninger,G
AU  - Dührsen,U
AU  - Serve,H
AU  - Berdel,W E
TI  - Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
SN  - 1569-8041
PY  - 2012///0713
KW  - Aged
KW  - Aged, 80 and over
KW  - Aminoglycosides
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Cytarabine
KW  - Daunorubicin
KW  - Disease-Free Survival
KW  - Female
KW  - Gemtuzumab
KW  - Humans
KW  - Induction Chemotherapy
KW  - Leukemia, Myeloid, Acute
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Survival Analysis
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdr346
ER  -